News Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 12:50:16 16/06/2025 pm IST			5-day change	1st Jan Change
1,480.50 ^DKK	-0.03%		-0.64%	-0.47%

09:50am	Genmab's Epcoritamab Combination Shows High Response Rates in Cancer Patients	MT
09/06	Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM

Genmab's Epcoritamab Combination Shows High Response Rates in Cancer Patients	09:50am	MT
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)	15/06	AQ
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)	15/06	GL
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)	15/06	BU
Grant of Restricted Stock Units and Warrants to Employees in Genmab	12/06	GL
Transactions in Connection with Share Buy-back Program	10/06	GL
Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM	09/06
AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength	09/06	MT
GENMAB : Beaten up share price offers an opportunity	06/06
Genmab's Rina-S shows promising efficacy in difficult-to-treat uterine cancer	03/06	FW
Sector Update: Health Care Stocks End Higher Late Afternoon	03/06	MT
Genmab A/S : Rina-S Update at ASCO 2025	03/06	PU
Genmab Says New Trial Data Shows 'Encouraging Anti-Tumor Activity' for Rinatabart Sesutecan	03/06	MT
Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial	03/06	CI
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial	03/06	BU
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial	03/06	GL
Transactions in Connection with Share Buy-back Program	02/06	GL
RBC lowers target price for Genmab to DKK 2,000 (2,300), reiterates outperform rating - BN	30/05	FW
RBC Cuts Price Target on Genmab to DKK2,000 From DKK2,300, Keeps Outperform Rating	29/05	MT
Genmab A/S - Transactions in Connection with Share Buy-back Program	27/05	AQ
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference	27/05	GL
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference	27/05	AQ
Transactions in Connection with Share Buy-back Program	26/05	GL
Deutsche Bank lowers target price for Genmab to DKK 1,750 (1,900), reiterates buy recommendation	23/05	FW
Redburn lowers target price for Genmab to DKK 2,700 (2,750), reiterates buy recommendation - BN	23/05	FW

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : Beaten up share price offers an opportunity

June 06, 2025 at 06:10 pm IST

Genmab: From now on, courage to the most patient

April 01, 2025 at 08:27 pm IST